Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReproductive Health & FertilityAetna Male Infertility Prior Auth Policy Update | …
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Male Infertility Injectable Medication Precertification Request

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and requirements governing precertification requests for injectable medications used to treat male infertility for Aetna members; affects prescribing providers requesting authorization for these medications. Authorizations are valid for 6 months.

    Policy Summary
    PayerAetna
    PolicyMale Infertility Injectable Medication Precertification Request
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed precertification form with required clinical documentation and lab work to obtain prior authorization valid for 6 months.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsauthorization validity
    2 pagesform length
    Lab work requiredsupporting documentation

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Phone/Faxprecertification contact

    Coverage Criteria for Injectable Male Infertility Medications

    Medical necessity elements (form-driven)

    Covered when ALL of the following documented elements are provided:

    Essential documentation: Completed precertification form with required clinical information and submitted lab work (sperm analysis, testosterone, FSH)

    Form requests dates and values for labs and sperm analysis

    Indication-specific criteria for hCG: Documented diagnosis of hypogonadotropic hypogonadism secondary to pituitary deficiency AND patient is undergoing infertility treatment or actively trying to conceive

    Checkboxes on form capture this; applies to hCG (Novarel, Pregnyl)

    Indication-specific criteria for menopausal gonadotropins and recombinant follitropins: Clinical evidence of primary or secondary hypogonadotropic hypogonadism documented; documentation whether patient has primary testicular failure must be provided and may affect coverage

    Form asks whether medication will be used with hCG for induction of spermatogenesis

    Gonal-F/Follistim prior therapy: For Follistim AQ, documented failure of Gonal-F or Gonal-FRFF (with dates of trial/failure) OR documented contraindication/intolerance/allergy to Gonal-F or Gonal-FRFF

    Form specifically requests dates of prior trials and failure or notes of contraindication/intolerance

    The precertification form explicitly asks whether the patient has primary testicular failure and whether prior sterilization procedures have occurred; these items are captured as required clinical queries that inform coverage decisions. Responses indicating primary testicular failure or prior sterilization serve as alternative or potentially exclusionary clinical findings that may affect approval for certain gonadotropin therapies.

    The form does not include a discrete "not medically necessary" statement; instead it requires completion of specified clinical fields to support approval. Failure to provide the requested documentation — including the completed checkboxes for diagnosis, prior product trials, and the lab work referenced elsewhere on the form — may jeopardize authorization even though the form itself does not label any scenario explicitly as "not medically necessary."

    Coding and Product Selections

    ICD codes (placeholders)ICD-10
    ICDPrimary ICD Code; Secondary ICD Code; Other ICD Code (placeholders captured on form)
    Administration CPT codes (placeholder)CPT
    CPTAdministration code(s) (CPT): (placeholders)
    Medication products (form selections)mixed
    NDC/HCPCSMedication product selections listed (hCG 10,000 unit vial; Novarel or Pregnyl 10,000 unit vial; Menopur or Repronex 75 IU vial; Lupron; Zoladex; LHRH; Gonal-F (450 IU vial, 1050 IU vial); Gonal-F RFF (75 IU vial, 300 IU pen/redi-ject, 450 IU pen/redi-ject, 900 IU pen/redi-ject); Follistim AQ (75 IU vial, 150 IU cartridge, 300 IU cartridge, 600 IU cartridge, 900 IU cartridge) )

    Precertification and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Precertification (prior authorization) is required for injectable male infertility medications. All fields on the precertification request form must be completed and legible. Authorizations are valid for 6 months from the approval date.

    • All fields on the precertification request must be completed for review
    • Authorizations are valid for 6 months
    Documentation Required

    Required Clinical Documentation

    Required clinical information must be completed in its entirety for all precertification requests. Lab work must be submitted with the request (most recent sperm analysis, testosterone, and FSH with dates).

    • Submit most recent sperm analysis (count, volume, clarity, motility) with date
    • Submit testosterone level with date

    Background

    The form collects clinical evidence to support use of gonadotropins, GnRH/LHRH analogs, and recombinant follitropins for male infertility. It requests documentation of diagnoses such as hypogonadotropic hypogonadism (including whether it is secondary to pituitary deficiency), whether the patient is actively attempting conception, and whether medications will be used in combination with hCG for induction of spermatogenesis. For recombinant products (for example, Follistim AQ), the form also requests prior product trial information — specifically whether there is a documented failure of Gonal‑F/Gonal‑FRFF and the dates of those trials — and asks about contraindications or intolerance to those products. Laboratory data (e.g., sperm analysis, testosterone, FSH) are required elsewhere on the form to complete the clinical picture for precertification review.

    Definitions

    Hypogonadotropic hypogonadism — definition and form queries
    DefinitionHypogonadotropic hypogonadism: diagnosis queried as indication for hCG, menopausal gonadotropins, GnRH/LHRH, and recombinant follitropin products when secondary to pituitary deficiency and associated with infertility or active attempts to conceive.
    Clinical evidence requestedForm asks whether there is clinical evidence of primary or secondary hypogonadotropic hypogonadism for menopausal gonadotropins and recombinant follitropins.
    Associated treatment contextForm specifically asks if the patient is undergoing infertility treatment or actively trying to conceive when requesting hCG.
    Combination useForm asks whether the medication will be used with hCG for induction of spermatogenesis (relevant for menopausal gonadotropins and follitropins).
    Primary testicular failure — form queries and implications
    Policy Summary
    PayerAetna
    PolicyMale Infertility Injectable Medication Precertification Request
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed precertification form with required clinical documentation and lab work to obtain prior authorization valid for 6 months.
    SourceLink
    On This Page
    Coverage Criteria for Injectable Male Infertility MedicationsCoding and Product SelectionsPrecertification and Provider RequirementsBackgroundDefinitions
  1. Submit FSH level with date
  2. Provide answers to all clinical questions on the request form
  3. Note

    Prior Product Trial Information Requested

    For Follistim AQ requests, indicate whether the patient has a documented failure of Gonal‑F or Gonal‑FRFF and provide dates of the trial and failure. If applicable, document any contraindication, intolerance, or allergy to Gonal‑F or Gonal‑FRFF.

    • If prior product trial = failure, include trial and failure dates
    • If prior product not tolerated, indicate contraindication/intolerance/allergy
    Denial Risk

    Fraud / Incomplete Information

    Any person who knowingly submits false information or conceals material information to obtain authorization may be committing insurance fraud and is subject to criminal and civil penalties. The plan may request additional information or clarification to evaluate requests.

    • Providing materially false information or concealing material information may be considered fraud
    • Fraud may result in criminal and civil penalties
    • Plan may request additional information to evaluate requests
    Definition
    Primary testicular failure: condition queried on the form as an alternative or exclusionary diagnosis when considering menopausal gonadotropins and recombinant follitropin products.
    Form questionThe form includes explicit yes/no checkboxes asking whether the patient has primary testicular failure for menopausal gonadotropins and for urofollitropins/recombinant follitropins.
    Impact on therapyPresence of primary testicular failure is queried alongside whether the medication will be used with hCG for induction of spermatogenesis, indicating it may affect coverage or treatment choice.
    Applicability to agentsPrimary testicular failure is assessed for Menopur/Repronex and for follitropin products (Gonal-F, Gonal-FRFF, Follistim AQ).